DiaMedica Therapeutics (DMAC) to Release Earnings on Wednesday

DiaMedica Therapeutics (NASDAQ:DMAC) will issue its quarterly earnings data after the market closes on Wednesday, August 7th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

DiaMedica Therapeutics (NASDAQ:DMAC) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.02. On average, analysts expect DiaMedica Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

DiaMedica Therapeutics Stock Performance

Shares of DiaMedica Therapeutics stock traded down $0.10 during midday trading on Tuesday, reaching $3.35. 18,426 shares of the company’s stock traded hands, compared to its average volume of 50,318. The company has a market cap of $143.18 million, a price-to-earnings ratio of -6.16 and a beta of 1.50. The company’s 50 day simple moving average is $2.97 and its 200 day simple moving average is $2.90. DiaMedica Therapeutics has a 52 week low of $1.94 and a 52 week high of $3.81.

Analyst Ratings Changes

Separately, Craig Hallum initiated coverage on shares of DiaMedica Therapeutics in a report on Wednesday, April 24th. They set a “buy” rating and a $8.00 price target on the stock.

Insider Buying and Selling

In other news, major shareholder Koch Thomas Von bought 1,200,000 shares of the company’s stock in a transaction that occurred on Friday, June 28th. The shares were purchased at an average price of $2.50 per share, for a total transaction of $3,000,000.00. Following the acquisition, the insider now directly owns 5,526,435 shares of the company’s stock, valued at approximately $13,816,087.50. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 7.20% of the company’s stock.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.